Strategies for improving outcomes in NSCLC: a look to the future - PubMed (original) (raw)
Review
doi: 10.1016/j.lungcan.2013.08.025. Epub 2013 Sep 8.
Solange Peters, Paul Baas, Elisabeth Brambilla, Federico Cappuzzo, Dirk De Ruysscher, Wilfried Ernst Erich Eberhardt, Enriqueta Felip, Dean Fennell, Antonio Marchetti, Luis Paz-Ares, Alex A Adjei
Affiliations
- PMID: 24094287
- DOI: 10.1016/j.lungcan.2013.08.025
Free article
Review
Strategies for improving outcomes in NSCLC: a look to the future
Rolf Stahel et al. Lung Cancer. 2013 Dec.
Free article
Abstract
Advances in the management of non-small cell lung cancer (NSCLC) over the past 30 years have led to small increases in 5-year survival rates across Europe, though further improvements may require new treatment strategies. In order to improve efficiency and reduce the cost of development, future trials for new targeted agents in NSCLC should aim to recruit patients on the basis of tumour biology rather than clinical characteristics. However, identification of predictive biomarkers is required to maximise the benefits of new approaches and expedite the drug development process. Nevertheless, the NSCLC landscape is changing rapidly, and recent improvements in our understanding of the molecular biology of the disease will help in the identification of novel targeted agents as well as assisting in the development of personalised strategies for the numerous small subsets of defined NSCLC. Progress in imaging and treatment delivery is also likely to improve outcomes for patients with the disease. This article outlines recent progress in the treatment of NSCLC, identifies current challenges and describes proposals for improving the future management of the disease. It is hoped that implementation of some of these strategies will go some way to improving the outlook for patients with NSCLC.
Keywords: Biomarkers; Clinical trials; Lung cancer; Management; Molecular profiling; Outcomes; Pathogenesis; Treatment.
Copyright © 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.
Similar articles
- Molecular predictive and prognostic markers in non-small-cell lung cancer.
Coate LE, John T, Tsao MS, Shepherd FA. Coate LE, et al. Lancet Oncol. 2009 Oct;10(10):1001-10. doi: 10.1016/S1470-2045(09)70155-X. Lancet Oncol. 2009. PMID: 19796752 Review. - Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Custodio A, de Castro J. Custodio A, et al. Crit Rev Oncol Hematol. 2012 Jun;82(3):338-60. doi: 10.1016/j.critrevonc.2011.08.003. Epub 2011 Sep 9. Crit Rev Oncol Hematol. 2012. PMID: 21908201 Review. - New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease.
Rengan R, Maity AM, Stevenson JP, Hahn SM. Rengan R, et al. Clin Cancer Res. 2011 Jul 1;17(13):4192-9. doi: 10.1158/1078-0432.CCR-10-2760. Epub 2011 May 16. Clin Cancer Res. 2011. PMID: 21576083 Review. - Tissue sampling in lung cancer: a review in light of the MERIT experience.
Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J. Reck M, et al. Lung Cancer. 2011 Oct;74(1):1-6. doi: 10.1016/j.lungcan.2011.05.002. Epub 2011 Jun 11. Lung Cancer. 2011. PMID: 21658788 Review. - Predictive markers in the adjuvant therapy of non-small cell lung cancer.
Filipits M, Pirker R. Filipits M, et al. Lung Cancer. 2011 Dec;74(3):355-63. doi: 10.1016/j.lungcan.2011.06.005. Epub 2011 Aug 31. Lung Cancer. 2011. PMID: 21885151 Review.
Cited by
- Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer.
Yu X, Liu J, Qiu H, Hao H, Zhu J, Peng S. Yu X, et al. Bosn J Basic Med Sci. 2021 Apr 1;21(2):198-207. doi: 10.17305/bjbms.2020.4746. Bosn J Basic Med Sci. 2021. PMID: 32530390 Free PMC article. - Lgr6: From Stemness to Cancer Progression.
Cortesi E, Ventura JJ. Cortesi E, et al. J Lung Health Dis. 2019 Jun 18;3(1):12-15. Epub 2019 Feb 5. J Lung Health Dis. 2019. PMID: 31236545 Free PMC article. - Very Early Response Evaluation by PET/MR in Patients with Lung Cancer-Timing and Feasibility.
Langer NH, Langer SW, Johannesen HH, Hansen AE, Costa J, Klausen TL, Forman J, Olin A, Rasmussen SH, Sørensen JB, Löfgren J, Kjær A, Fischer BM. Langer NH, et al. Diagnostics (Basel). 2019 Mar 26;9(1):35. doi: 10.3390/diagnostics9010035. Diagnostics (Basel). 2019. PMID: 30917539 Free PMC article. - WNT signaling - lung cancer is no exception.
Rapp J, Jaromi L, Kvell K, Miskei G, Pongracz JE. Rapp J, et al. Respir Res. 2017 Sep 5;18(1):167. doi: 10.1186/s12931-017-0650-6. Respir Res. 2017. PMID: 28870231 Free PMC article. Review. - Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML.
Yang B, Yao J, Li B, Shao G, Cui Y. Yang B, et al. Mol Cell Biochem. 2017 Dec;436(1-2):87-97. doi: 10.1007/s11010-017-3081-2. Epub 2017 Jul 25. Mol Cell Biochem. 2017. PMID: 28744813
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous